Quest Diagnostics Inc. (DGX) Stock Price

DGXStock

$242.76+35.47%52W

Market Cap$26.79B

P/E26.35x

PEG Ratio2.04

Div yield2.10%

Beta0.54

DGX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)3.92%

Price vs S&P 500 (4W)3.12%

PEG Ratio2.04

VGM Score50.38

P/E Ratio (Annual)26.35x

Indicated Dividend Yield (Annual)2.10%

P/CF (Annual)13.86x

Book Value / Share (Quarterly)$68.33

P/TBV (Annual)3.49x

Indicated Dividend (Annual)$3.44

Revenue Growth (3Y)3.74%

Cash Flow / Share (Quarterly)$12.26

Payout Ratio (TTM)34.18%

Price vs S&P 500 (YTD)27.07%

Gross Margin (TTM)33.19%

Net Profit Margin (TTM)9.19%

EPS (TTM)$9.44

10-Day Avg Trading Volume0.85M

EPS Excl Extra (TTM)$9.44

Revenue Growth (5Y)3.18%

EPS (Annual)$8.78

Dividend / Share (Annual)$3.19

ROI (Annual)7.61%

Gross Margin (Annual)33.32%

Net Profit Margin (5Y Avg)11.02%

Cash / Share (Quarterly)$5.69

P/E Basic Excl Extra (TTM)24.62x

Revenue Growth QoQ (YoY)10.21%

EPS Growth (5Y)-3.56%

P/E Normalized (Annual)26.35x

ROA (Last FY)6.11%

Revenue Growth TTM (YoY)9.87%

EBITD / Share (TTM)$15.83

ROE (5Y Avg)17.45%

Operating Margin (TTM)14.10%

Cash Flow / Share (Annual)$12.35

P/B Ratio3.48x

P/B Ratio (Quarterly)3.12x

Net Income / Employee (Annual)$21,600

EV / Revenue (TTM)2.70x

Net Interest Coverage (TTM)6.38x

ROA (TTM)6.43%

EPS Growth QoQ (YoY)14.49%

EV / EBITDA (TTM)17.50x

EPS Incl Extra (Annual)$8.78

Current Ratio (Annual)1.04x

Quick Ratio (Quarterly)1.28x

3-Month Avg Trading Volume0.91M

52-Week Price Return35.47%

EV / Free Cash Flow (Annual)22.93x

P/E Incl Extra (TTM)24.62x

Revenue / Employee (TTM)$251,300

Tangible BV / Share (Quarterly)$53.13

P/S Ratio (Annual)2.37x

Asset Turnover (Annual)0.68x

52-Week High$247.19

Operating Margin (5Y Avg)15.58%

EPS Excl Extra (Annual)$8.78

CapEx CAGR (5Y)4.74%

Tangible BV CAGR (5Y)-0.21%

26-Week Price Return15.85%

Quick Ratio (Annual)0.80x

13-Week Price Return23.73%

Total Debt / Equity (Annual)0.82x

Current Ratio (Quarterly)1.59x

Enterprise Value$31.16B

Revenue / Share Growth (5Y)7.07%

Asset Turnover (TTM)0.70x

Book Value / Share Growth (5Y)5.10%

Revenue / Employee (Annual)$239,900

Inventory Turnover (Annual)39.03x

Pretax Margin (Annual)11.94%

Cash / Share (Annual)$3.82

3-Month Return Std Dev25.83%

Gross Margin (5Y Avg)34.87%

Net Income / Employee (TTM)$23,100

EBITDA CAGR (5Y)-3.79%

EBITDA Interim CAGR (5Y)-2.29%

ROE (Last FY)13.84%

Net Interest Coverage (Annual)7.05x

EPS Basic Excl Extra (Annual)$8.78

P/FCF (TTM)19.38x

Receivables Turnover (TTM)7.49x

EV / Free Cash Flow (TTM)23.10x

Total Debt / Equity (Quarterly)0.75x

EPS Incl Extra (TTM)$9.44

Receivables Turnover (Annual)8.14x

ROI (TTM)8.18%

Dividend Growth Rate (5Y)7.42%

P/S Ratio (TTM)2.26x

Pretax Margin (5Y Avg)14.53%

Revenue / Share (Annual)$97.65

Tangible BV / Share (Annual)$50.31

Forward P/E20.09x

Free OCF CAGR (5Y)-3.05%

Price vs S&P 500 (52W)16.91%

P/E Ratio (TTM)24.62x

EPS Growth TTM (YoY)13.01%

Year-to-Date Return39.90%

5-Day Price Return-0.46%

EPS Normalized (Annual)$8.78

ROA (5Y Avg)7.92%

Net Profit Margin (Annual)8.99%

Month-to-Date Return4.18%

Cash Flow / Share (TTM)$10.91

EBITD / Share (Annual)$15.13

EPS Growth (3Y)3.07%

Operating Margin (Annual)14.10%

LT Debt / Equity (Annual)0.72x

P/CF (TTM)13.74x

ROI (5Y Avg)10.05%

P/E Excl Extra (TTM)24.62x

LT Debt / Equity (Quarterly)0.75x

EPS Basic Excl Extra (TTM)$9.44

P/TBV (Quarterly)4.01x

Payout Ratio (Annual)35.58%

P/B Ratio (Annual)2.69x

Dividend / Share (TTM)$3.27

Inventory Turnover (TTM)36.78x

Pretax Margin (TTM)12.15%

Book Value / Share (Annual)$65.18

Price vs S&P 500 (13W)21.78%

Net Margin Growth (5Y)-9.92%

Dividend Yield (TTM)1.39%

Beta0.54x

P/FCF (Annual)19.24x

Revenue / Share (TTM)$103.21

ROE (TTM)14.49%

52-Week Low$171.18

vGradeC

gGradeD

mGradeB

vgmGradeC

DGX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 23, 2026	$2.82	$3.12	+10.51%(+$0.30)
Q1 2026	Apr 21, 2026	$2.37	$2.50	+5.61%(+$0.13)
Q4 2025	Feb 10, 2026	$2.36	$2.42	+2.63%(+$0.06)
Q3 2025	Oct 21, 2025	$2.50	$2.60	+3.85%(+$0.10)
Q2 2025	Jul 22, 2025	$2.57	$2.62	+1.87%(+$0.05)

DGX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.79

3.83

Industry Peers — Health Services(30)

Symbol	Value Score	Growth Score	Momentum Score	Price
DGXQuest Diagnostics Inc.	C	D	B	$242.76
NTRANatera, Inc. Common Stock	F	A	B	$326.26
LHLabcorp Holdings Inc.	C	D	B	$335.11
GHGuardant Health, Inc. Common Stock	F	A	B	$161.50
CAICaris Life Sciences, Inc. Common Stock	F	A	C	$25.63
RDNTRadNet, Inc. Common Stock	D	C	B	$74.61
BLLNBillionToOne, Inc. Class A Common Stock	F	F	D	$93.24
CELCCelcuity Inc. Common Stock	—	—	C	$88.44
GRALGRAIL, Inc. Common Stock	D	A	B	$80.00
VCYTVeracyte, Inc.	D	A	C	$43.34
CDNACareDx, Inc.	D	B	A	$49.79
PSNLPersonalis, Inc. Common Stock	F	D	A	$17.07
FTREFortrea Holdings Inc. Common Stock	B	F	A	$18.81
FRNMFreenome, Inc. Common stock	—	F	A	$14.79
LMRILumexa Imaging Holdings, Inc. Common Stock	C	C	C	$11.51
CSTLCastle Biosciences, Inc. Common Stock	D	B	B	$33.50
FLGTFulgent Genetics, Inc. Common Stock	C	D	C	$19.61
YDESYD Bio Limited Ordinary Shares	—	—	C	$4.80
BDSXBiodesix, Inc. Common Stock	D	B	A	$26.83
XGNExagen Inc. Common Stock	D	B	C	$7.39
PCSCPerceptive Capital Solutions Corp Class A Ordinary Shares	—	F	B	$11.95
BNRBurning Rock Biotech Limited American Depositary Shares	B	F	D	$10.19
SERASera Prognostics, Inc. Class A Common Stock	D	D	D	$2.07
MDXHMDxHealth SA Ordinary Shares	B	B	F	$0.72
ADVBAdvanced Biomed Inc. Common Stock	A	—	A	$9.70
AMSAmerican Shared Hospital Services	A	C	D	$1.47
ACONAclarion, Inc. Common Stock	—	B	F	$2.40
BGLCBioNexus Gene Lab Corp Common stock	B	F	F	$1.55
ACONWAclarion, Inc. Warrant	—	—	C	$0.03
EXASExact Sciences Corp	F	B	B	$0.00
YDESWYD Bio Limited Warrants	—	—	D	$0.42

About Quest Diagnostics Inc.

Quest Diagnostics is the leading independent provider of diagnostic testing services in the United States, generating over 97% of revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse screening delivered via a nationwide network of approximately 2,400 patient service centers and partnerships with healthcare providers. The company's diagnostic solutions segment provides supplementary services including clinical trials testing, risk-assessment services, and healthcare information technology solutions.